01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health (CAH) reported first-quarter fiscal 2026 results (quarter ended September 30, 2025) that were strong across the board and prompted a raised full-year outlook.
Revenue rose 22% year over year to $64.0 billiona, GAAP operating earnings rose 18% to $668 million, and GAAP diluted EPS rose 11% to $1.88. On a non-GAAP basis, operating earnings grew 37% to $857 million and diluted EPS grew 36% to $2.55, with segment profit growth in all five operating segments. The Pharmaceutical and Specialty Solutions segment, which drives most of the revenue, delivered 23% revenue growth and 26% segment profit growth, while the Other category (including at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics) grew segment profit 60%.
Management raised fiscal 2026 non-GAAP diluted EPS guidance to $9.65b-$9.85 from $9.30-$9.50, and raised adjusted free cash flow guidance to $3.0-$3.5 billion from $2.75-$3.25 billion. The raise reflects the strong quarter and expected contributions from the Solaris Health acquisition, which is expected to close in early November. Investors should note that the guidance increase is partly offset by higher interest and other expense (raised to about $325 million from about $275 million) due to acquisition financing, and that GAAP net earnings growth (8%) lagged non-GAAP growth (33%) because of acquisition-related costs, amortization, and a lower non-GAAP tax rate.
Cash flow also improved sharply, with operating cash flow of $973 millionc versus a $1.6 billion outflow a year earlier, though this quarter benefited from working capital timing, including a $2.1 billion increase in accounts payable. The filing also flags risks that warrant monitoring, including a Department of Justice investigation focused on potential Anti-Kickback Statute and False Claims Act violations, pressure on branded drug pricing from legislative or executive action, generic deflation, and execution risk from recent and pending acquisitions.
The balance sheet shows a shareholders' deficit of $2.7 billiond, total debt (long-term obligations plus current portion) rising to about $9.0 billion from about $8.5 billion, and cash rising to $4.6 billion. The company also initiated a $375 million accelerated share repurchase program during the quarter.
02—Key points
Key Highlights
- Revenue grew 22% to $64.0 billion, led by a 23% increase in Pharmaceutical and Specialty Solutions revenue to $59.2 billion driven by brand and specialty sales growth
- Non-GAAP operating earnings rose 37% to $857 million and non-GAAP diluted EPS rose 36% to $2.55, with segment profit growth across all five operating segments
- GAAP diluted EPS increased 11% to $1.88; GAAP net earnings attributable to Cardinal Health grew 8% to $450 million
- Fiscal 2026 non-GAAP diluted EPS guidance raised to $9.65-$9.85 (+17% to +20%) from $9.30-$9.50, and adjusted free cash flow guidance raised to $3.0-$3.5 billion
- Interest and other expense outlook increased to about $325 million from about $275 million to reflect Solaris Health acquisition financing; the Solaris Health acquisition is expected to close in early November
- Operating cash flow was $973 million versus a $1.6 billion outflow in the prior-year quarter, though aided by a $2.1 billion increase in accounts payable
- Ongoing DOJ investigation into potential Anti-Kickback Statute and False Claims Act violations is cited as a material risk factor
03—Questions
Frequently Asked Questions
Why did Cardinal Health raise its fiscal 2026 EPS guidance?
Management raised non-GAAP diluted EPS guidance by $0.35 at the midpoint, to $9.65-$9.85, citing strong first-quarter performance and expected contributions from the Solaris Health acquisition. Segment profit growth expectations were also raised for Pharmaceutical and Specialty Solutions (to 16%-19% from 11%-13%) and Other (to 29%-31% from 25%-27%).
Why did GAAP earnings grow much less than non-GAAP earnings?
The gap is driven by items management excludes from non-GAAP results, including $104 million of amortization and other acquisition-related costs, $64 million of acquisition-related cash and share-based compensation costs, and $20 million of restructuring charges. Non-GAAP results also benefited from a lower effective tax rate (21.9% versus 24.1% on a GAAP basis) and a lower share count. GAAP operating earnings grew 18% versus 37% on a non-GAAP basis.
Is the strong cash flow sustainable?
Not necessarily on a quarterly basis. First-quarter operating cash flow of $973 million benefited from a $2.1 billion increase in accounts payable, which often reflects timing of payments to suppliers. The company's full-year adjusted free cash flow outlook of $3.0-$3.5 billion implies that cash generation will need to continue at a healthy pace across the remaining quarters to meet the target.
What are the main risks flagged in the filing?
The release highlights a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations, uncertainty around branded pharmaceutical pricing from legislative or executive action, generic drug deflation, customer contract pressures, supply disruptions, and integration risks from recent and pending acquisitions such as Solaris Health. The company also reports a shareholders' deficit of $2.7 billion and total debt that rose to about $9.0 billion.
How much capital is being returned to shareholders?
Cardinal Health initiated a $375 million accelerated share repurchase program in the first quarter and paid $129 million in common dividends. The lower diluted share count (239 million versus 245 million a year earlier) also contributed to EPS growth. Management expects diluted weighted-average shares of about 238 million for the full year.
04—Continue